Ibro Injection:

Prevents bone loss in postmenopausal osteoporosis
Proven efficacy in reducing the risk of osteoporotic fractures
Better patient compliance than weekly alendronate therapy
Improved G.I. tolerability.
Indication and Usage Postmenupausal osteoporosis. 3mg every 3 months
Reduction in bone damage in bone metastases in breast cancer. 6mg every 3 to 4 weeks.
Hypercalcemia of malignancy 2 to 4mg.